Capello will lead Biogen's business planning, tax, treasury, internal audit, accounting, and investor relations functions. He will report to Michel Vounatsos, CEO of Biogen, will be a member of the executive committee, and will be based in Cambridge, Mass.
Capello brings 26 years of experience in finance. Most recently he was executive VP and CFO of Beacon Health Options Inc.
His previous experience includes founding and running his own company, Monomy Advisors, and serving as CFO of Ortho Clinical Diagnostics, Boston Scientific Corp., and Perkin Elmer.
Capello is a certified public accountant. He holds a B.S. in Business Administration from the University of Vermont and an M.B.A. in Accounting from Harvard Business School.
Biogen discovers, develops, and delivers therapies for people living with serious neurological and neurodegenerative diseases.
The company has a leading portfolio of medicines to treat multiple sclerosis and spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).
Biogen also manufactures and commercializes biosimilars of advanced biologics.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval